Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC01
- Development stage
- Preclinical
- Lead developer
- GlioCure
- Modality
- Peptides
01
Overview
GC01 is a synthetic anti-tumor peptide developed by GlioCure that selectively inhibits tubulin beta 3 chain (TUBB3) polymerization in tumor cells overexpressing TUBB3, blocking cell division in a tumor-specific manner. It has demonstrated in vivo activity against glioblastoma models and is intended for combination with delivery devices like Defymed's ExOlin® for prolonged administration in brain tumors. Primarily targeting high-grade glioblastoma and other TUBB3-overexpressing solid tumors such as triple-negative breast cancer, it addresses resistance to standard therapies.
02
Targets
TUBB3 (Tubulin beta-3 chain)
Beyond the preview
Go deeper on GC01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC01.